UVA Brain Cancer Trials Lead to FDA Accelerated Approval of Medication

	Tweet

David Schiff, M.D., and colleagues at the University of Virginia Cancer Center were key researchers in a large national clinical trial that has resulted in U.S. Food and Drug Administration (FDA) accelerated approval of the medication bevacizumab, or Avastin, to treat the recurrence of glioblastoma. Glioblastoma is the most aggressive malignant primary brain tumor in adults and is nearly always fatal.

“In our clinical trials, we saw 30 to 40 percent of patients with dramatic shrinkage of tumors,” says Schiff, professor of neurology, neurosurgery and medicine in the UVA School of Medicine. “It’s not a cure, but this treatment does improve quality of life and prolong life.”

Glioblastoma affects approximately 10,000 people per year in the United States
and, glioblastoma tumors nearly always return following initial treatment. With traditional therapy of radiation and the medication temozolomide, less than 21 percent of patients live for six months after recurrence of the disease. The median overall survival is 30 weeks or less.

Of the 167 patients enrolled in the multi-center Phase II study, 85 were treated with bevacizumab alone. Half lived for nine months or longer and nearly one third lived six months without their disease getting worse. All patients enrolled in the study had previously progressed in their disease following initial treatment with temozolomide and radiation had failed.

Bevacizumab is the first new treatment in more than a decade for people with previously treated glioblastoma.

“These results showed that bevacizumab should be a critical component of standard therapy for recurrence of this disease, and the FDA agreed,” says Schiff. “Now we plan to study bevacizumab as a treatment for newly diagnosed glioblastoma and in combinations for recurrent malignant glioma.”

Other premiere institutions involved in the national clinical trial included Duke University’s Brain Tumor Center, Brigham and Women’s Hospital of Harvard University, Memorial Sloan-Kettering Cancer Center and the University of Texas MD Anderson Cancer Center.

Source: University of Virginia Health System

RELATED STORIES:
Dana-Farber Hosting Live Twitter Chat on Head and Neck Cancers   Tobacco use linked to worse outcomes in HPV-positive head and neck cancer, U-M study finds   Brain tumor discovery could lead to new treatment   Genetics of children’s brain tumour unlocked   Study Compares Treatment Options for Patients with Brain Metastases   Most patients can speak and swallow after combination treatment for head and neck cancer   Could smoking pot cut risk of head, neck cancer?   Novel Vaccine Curbs Brain Tumor Growth, Increases Survival   Blood Pressure Compound May Benefit Brain Tumor Patients   Brain metastases hijack neuron-supporting cells to resist chemotherapy   New technique holds promise for rare eye cancer   New Imaging Analysis Predicts Brain Tumor Survival   Researchers Identify Best Treatments for Long-Term Survival in Brain Tumor Patients   Acrylamide not tied to thyroid, head-neck cancers   Immune deficiency linked to a type of eye cancer   Variations in Five Genes Raise Risk for Most Common Brain Tumors   Brain Cancer Experts and Resources at Johns Hopkins   Hyperbaric Oxygen Tested for Aggressive Brain Cancer   Acupuncture Reduces Pain and Dysfunction in Head and Neck Cancer Patients After Neck Dissection   New procedure to make brain surgery safer   Genetic Risk Factor Found for Head and Neck Cancer in Smokers   Alcohol and cancer: is drinking the new smoking?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]